RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -64.08% | -32.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.08% | -32.10% | |||
| Cost of Revenue | -40.79% | -85.12% | |||
| Gross Profit | -70.58% | 113,533.33% | |||
| SG&A Expenses | -43.13% | 102.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -97.60% | 1,290.91% | |||
| Total Operating Expenses | -44.62% | 14.78% | |||
| Operating Income | 36.86% | -58.43% | |||
| Income Before Tax | 89.14% | -1,252.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 89.16% | -1,254.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.16% | -1,254.79% | |||
| EBIT | 36.86% | -58.43% | |||
| EBITDA | 39.87% | -72.24% | |||
| EPS Basic | 89.12% | -1,250.00% | |||
| Normalized Basic EPS | 61.22% | -366.67% | |||
| EPS Diluted | 89.12% | -1,250.00% | |||
| Normalized Diluted EPS | 61.22% | -366.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||